Patent ID: 11897925
Assignee: SINAI HEALTH SYSTEM
Field: Pharmaceuticals (Chemistry)
Classification: CPC C  A | IPC A  C

Claim 4:
5. A method of treating a cancer associated with or characterized by a homologous recombination deficiency comprising administering to an individual in need thereof an effective amount of a CIP2A-TOPBP1 inhibitor comprising a peptide of TOPBP1 comprising residues 756 to 1000, 756 to 891, 776 to 851, or 830 to 851 of SEQ ID NO: 11, or a sequence having 95% identity thereto, and binds CIP2A or a fragment thereof; wherein binding of the peptide to CIP2A reduces the ability of TOPBP1 to interact with CIP2A or destabilizes or inhibits an existing CIP2A-TOPBP1 interaction, either directly or indirectly.